Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus.

Hepatoma Res · 2020 · PMC7597818 · PMID 33134550

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

However, in the phase III randomized, double blind, multicentre CheckMate-459 trial, nivolumab failed to show statistical significance in OS benefit though there was a clear trend of improvement in OS for patients treated with nivolumab compared to sorafenib [ Table 1 ] [ 77 ] .

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.